[go: up one dir, main page]

AU2002332560B2 - Compositions and methods relating to novel benzodiazepine compounds and targets thereof - Google Patents

Compositions and methods relating to novel benzodiazepine compounds and targets thereof Download PDF

Info

Publication number
AU2002332560B2
AU2002332560B2 AU2002332560A AU2002332560A AU2002332560B2 AU 2002332560 B2 AU2002332560 B2 AU 2002332560B2 AU 2002332560 A AU2002332560 A AU 2002332560A AU 2002332560 A AU2002332560 A AU 2002332560A AU 2002332560 B2 AU2002332560 B2 AU 2002332560B2
Authority
AU
Australia
Prior art keywords
cells
cell
agent
benzodiazepine
cell sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002332560A
Other languages
English (en)
Other versions
AU2002332560A1 (en
Inventor
Gary D. Glick
Anthony W. Opipari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/217,878 external-priority patent/US20030119029A1/en
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of AU2002332560A1 publication Critical patent/AU2002332560A1/en
Application granted granted Critical
Publication of AU2002332560B2 publication Critical patent/AU2002332560B2/en
Priority to AU2006201605A priority Critical patent/AU2006201605B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2002332560A 2001-08-15 2002-08-15 Compositions and methods relating to novel benzodiazepine compounds and targets thereof Ceased AU2002332560B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2006201605A AU2006201605B2 (en) 2001-08-15 2006-04-19 Compositions and methods relating to novel benzodiazepine compounds and targets thereof

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US31256001P 2001-08-15 2001-08-15
US60/312,560 2001-08-15
US31368901P 2001-08-20 2001-08-20
US60/313,689 2001-08-20
US39667002P 2002-07-18 2002-07-18
US60/396,670 2002-07-18
US10/217,878 2002-08-13
US10/217,878 US20030119029A1 (en) 1999-04-30 2002-08-13 Compositions and methods relating to novel benzodiazepine compounds and targets thereof
PCT/US2002/026171 WO2003015703A2 (fr) 2001-08-15 2002-08-15 Compositions et procedes relatifs a de nouveaux composes de benzodiazepine et leurs cibles

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2006201605A Division AU2006201605B2 (en) 2001-08-15 2006-04-19 Compositions and methods relating to novel benzodiazepine compounds and targets thereof

Publications (2)

Publication Number Publication Date
AU2002332560A1 AU2002332560A1 (en) 2003-05-29
AU2002332560B2 true AU2002332560B2 (en) 2006-01-19

Family

ID=27499087

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002332560A Ceased AU2002332560B2 (en) 2001-08-15 2002-08-15 Compositions and methods relating to novel benzodiazepine compounds and targets thereof

Country Status (8)

Country Link
EP (1) EP1423122A4 (fr)
JP (1) JP2005502652A (fr)
AU (1) AU2002332560B2 (fr)
CA (1) CA2457405A1 (fr)
MX (1) MXPA04001421A (fr)
NO (1) NO20041058L (fr)
NZ (1) NZ531117A (fr)
WO (1) WO2003015703A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8759340B2 (en) 2007-11-06 2014-06-24 The Regents Of The University Of Michigan Benzodiazepinone compounds useful in the treatment of skin conditions
US8791104B2 (en) 2005-11-01 2014-07-29 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones with therapeutic properties
US8809323B2 (en) 1999-04-30 2014-08-19 The Regents Of The University Of Michigan Therapeutic applications of pro-apoptotic benzodiazepines

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7144880B2 (en) 1999-04-30 2006-12-05 Regents Of The University Of Michigan Compositions relating to novel compounds and targets thereof
US20050113460A1 (en) * 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US20060025388A1 (en) 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
US7276348B2 (en) 1999-04-30 2007-10-02 Regents Of The University Of Michigan Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof
MXPA05011741A (es) * 2003-05-01 2006-05-12 Univ Michigan Composiciones y metodos que se relacionan con compuestos y objetivos novedosos de los mismos.
US20050272723A1 (en) * 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
WO2006074358A1 (fr) 2005-01-03 2006-07-13 The Regents Of The University Of Michigan Compositions et procedes concernant de nouveaux composes et leurs cibles
WO2007053193A2 (fr) 2005-06-01 2007-05-10 The Regents Of The University Of Michigan Préparations de benzodiazépine non solvatées et méthodes
EP1928465A1 (fr) * 2005-09-19 2008-06-11 Arrow Therapeutics Limited Dérivés de benzodiazépine pour le traitement d une infection par l hépatite c
US7759338B2 (en) 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
CA2659549C (fr) 2006-06-09 2013-07-30 The Regents Of The University Of Michigan Compositions et procedes associes a de nouveaux composes et leurs cibles
CA2783589A1 (fr) 2007-03-09 2008-09-18 The Regents Of The University Of Michigan Compositions et procedes en rapport avec de nouveaux composes et cibles de ceux-ci
ES2614498T3 (es) 2007-09-14 2017-05-31 The Regents Of The University Of Michigan Inhibidores de ATPasa F1F0 y métodos relacionados
JP5567573B2 (ja) 2008-09-11 2014-08-06 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン アリールグアニジンｆ１ｆ０−ａｔｐアーゼ阻害剤およびそれと関連する方法
WO2010121164A2 (fr) 2009-04-17 2010-10-21 The Regents Of The University Of Michigan Composés de 1,4-benzodiazépinone et leur utilisation dans le traitement du cancer
EP2470020A4 (fr) 2009-09-18 2013-03-13 Univ Michigan Composés de benzodiazépinone et méthodes de traitement les utilisant
JP5856064B2 (ja) 2009-11-17 2016-02-09 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 治療特性を有する１，４−ベンゾジアゼピン−２，５−ジオンおよび関連化合物
US9126978B2 (en) 2009-11-17 2015-09-08 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898861A (en) * 1987-03-26 1990-02-06 Hoffmann-La Roche Inc. Method for inhibiting the proliferation of tumor cells
WO2000066106A2 (fr) * 1999-04-30 2000-11-09 The Regents Of The University Of Michigan Applications therapeutiques de benzodiazepines pro-apoptotiques
US5776946A (en) * 1995-08-28 1998-07-07 Mcgeer; Patrick L. Peripheral benzodiazepine receptor ligands as antiinflammatory agents
WO1999058117A1 (fr) * 1998-05-13 1999-11-18 Sanofi-Synthelabo Utilisation de composes reduisant l'apoptose
FR2779963A1 (fr) * 1998-06-22 1999-12-24 Centre Nat Rech Scient Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer
US6277844B1 (en) * 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
CA2375542A1 (fr) * 1999-06-22 2000-12-28 James A. Dykens Compositions et procedes d'analyse de conditions infracellulaires et traitement par transert d'energie
US7005274B1 (en) * 1999-09-15 2006-02-28 Migenix Corp. Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass
WO2001051922A2 (fr) * 2000-01-14 2001-07-19 Mitokor Procedes pour identifier les agents liant le recepteur de benzodiazepine peripherique

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8809323B2 (en) 1999-04-30 2014-08-19 The Regents Of The University Of Michigan Therapeutic applications of pro-apoptotic benzodiazepines
US8791104B2 (en) 2005-11-01 2014-07-29 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones with therapeutic properties
US8759340B2 (en) 2007-11-06 2014-06-24 The Regents Of The University Of Michigan Benzodiazepinone compounds useful in the treatment of skin conditions

Also Published As

Publication number Publication date
NO20041058L (no) 2004-05-14
JP2005502652A (ja) 2005-01-27
CA2457405A1 (fr) 2003-02-27
MXPA04001421A (es) 2004-06-03
WO2003015703A3 (fr) 2003-11-13
NZ531117A (en) 2006-03-31
EP1423122A4 (fr) 2008-12-10
EP1423122A2 (fr) 2004-06-02
WO2003015703A2 (fr) 2003-02-27

Similar Documents

Publication Publication Date Title
US20030119029A1 (en) Compositions and methods relating to novel benzodiazepine compounds and targets thereof
AU2002332560B2 (en) Compositions and methods relating to novel benzodiazepine compounds and targets thereof
US8722667B2 (en) Compositions and methods for inhibiting the proliferation of cells
EP1143946B1 (fr) Applications therapeutiques de benzodiazepines pro-apoptotiques
US7276348B2 (en) Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof
AU2002332560A1 (en) Compositions and methods relating to novel benzodiazepine compounds and targets thereof
CA2524394C (fr) Nouvelles benzodiazepines, compositions de celles-ci et leurs utilisations
US20040176358A1 (en) Compositions and methods relating to novel compounds and targets thereof
AU2006201605B2 (en) Compositions and methods relating to novel benzodiazepine compounds and targets thereof
HK1063732A1 (en) Use of benzodiazepines for treating autoimmune diseases, inflammations, neoplasies, viral infections and atherosclerosis
HK1063732B (en) Use of benzodiazepines for treating autoimmune diseases, inflammations, neoplasies, viral infections and atherosclerosis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired